Most of the small protein kinase inhibitors that have been approved or are on the verge of getting approval for their clinical use, along with the majority of kinase inhibitors currently in the clinical trial phase, intend to target tyrosine kinases and are employed for the treatment of varied cancers. Here, WEE1 is linked to cancer.